Drug Profile
PL 3994
Alternative Names: PL-3994Latest Information Update: 29 Nov 2022
Price :
$50
*
At a glance
- Originator Palatin Technologies
- Class Antiasthmatics; Heart failure therapies; Natriuretic peptides
- Mechanism of Action Atrial natriuretic factor receptor A agonists; Diuretics; Natriuretic peptide stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Asthma
Highest Development Phases
- Phase II Heart failure
- No development reported Acute asthma